GENLISA™ SARS-CoV-2 (Covid-19) Delta/DeltaPlus Neutralizing Antibody (B.1.617.2, AY.1,AY.2) ELISA

ELISA for the Quantitative determination of neutralizing antibody to the SARS-CoV-2 Spike receptor binding domain (RBD) of Delta variant (India variant) in serum and plasma samples. One of the primaryWHO’s variants of concern, the delta coronavirus strain more was responsible for the second wave of the pandemic. Existing vaccines were only moderately effective against the variant. Therefore, the intended use of this Delta variant COVID-19 Neutralizing antibody ELISA is in the development of more efficacious vaccines and drug therapies. Detecting and quantifying neutralizing antibodies to SARS-CoV-2 offers important information in the evaluation of immune responses, development of vaccines and therapeutic drugs. As other Krishgen ELISA, these kits are based on monoclonal antibody detection for better sensitivity. Proprietary stabilizers and blockers for optimal signal:noise ratio, with specific antibodies allow for a robust ELISA. Features include a standard, ready-to-use protocol, and the option to run serum or plasma samples. The kit employs a blocking ELISA technique which mimics the virus neutralization process. Potent neutralizing antibodies often target the receptor interaction site in S1, disabling receptor interactions. The spike proteins of SARS-CoV-2 commonly bind to the human angiotensin converting enzyme 2 (ACE2) protein as a host receptor through their S1B domain. Receptor interaction is known to trigger irreversible conformational changes in coronavirus spike proteins enabling membrane fusion. SARS-CoV-2 initiates an immune response, which leads to the production of antibodies. These neutralizing antibodies disable host receptor interactions and prevent viral entry into the cell. They, therefore, also provide protection against future infection from SARS-CoV-2, as they remain in the circulatory system for months to years post infection.